Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCMSCs and Conditioned Medium for Cerebral Palsy
NCT04314687Phase 2Active, not recruiting
- Sponsor
- Prodia Stem Cell Indonesia
- Start
- Oct 2021
- Primary completion
- Jul 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of human umbilical cord mesenchymal stem cells in cerebral palsy (CP) (3 arms), sponsored by Prodia Stem Cell Indonesia. Primary endpoints: Gross Motor Function at 6 months and Cognitive Function at 6 months. Started Oct 2021; status: active, not recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on NCT04314687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314687.